Atossa Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Atossa Therapeutics has a total shareholder equity of $73.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $79.5M and $5.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$74.77m |
| Equity | US$73.68m |
| Total liabilities | US$5.80m |
| Total assets | US$79.48m |
Recent financial health updates
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Nov 12
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Jul 01Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Recent updates
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Nov 12Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go
Nov 08We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Jul 01Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Apr 26We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Jan 09Atossa Therapeutics: Still Gets An 'Incomplete' Rating
Oct 11We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Sep 25Atossa Therapeutics GAAP EPS of -$0.05
Aug 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
May 12A First Assessment On Atossa Therapeutics
Dec 10We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 02Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Sep 22Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Jul 17Atossa Therapeutics: Hope Springs Eternal
Jun 30Atossa Therapeutics to be included in the Russell 2000, 3000 indexes
Jun 16Atossa reaches a two-year high ahead of data readout for breast cancer therapy
Jun 07Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Apr 02Atossa updates on single-patient study for Endoxifen
Feb 04Atossa halts Endoxifen breast cancer study after positive data
Feb 02Atossa Therapeutics prices ~$25M direct offering, stock -23% PM
Jan 06Atossa Therapeutics prices $14M registered direct offering
Dec 17We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 10
Atossa Therapeutics plummets 38% after it raises $20M in public offering
Dec 09Financial Position Analysis
Short Term Liabilities: ATOS's short term assets ($77.1M) exceed its short term liabilities ($5.8M).
Long Term Liabilities: ATOS has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ATOS is debt free.
Reducing Debt: ATOS has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATOS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ATOS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.6% each year